“Patients in the FSGS trial and for a diabetic kidney disease study also using DMX-200 have already been allowed by the Australia drug regulator to stay on the treatment through the Special Access Scheme, demonstrating some physician confidence in its benefit to patients. “ * from above article.
There lies the answer to the question re: which trial participants got special access for ongoing treatment- I.e. BOTH!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.005(0.90%) |
Mkt cap ! $333.0M | |||
| Open | High | Low | Value | Volume |
| 55.5¢ | 57.5¢ | 54.5¢ | $548.2K | 976.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 24827 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 21668 | 2 |
View Market Depth
| Last trade - 14.41pm 16/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |